CTLA4 and melanoma: Furthermore, the administration of recombinant murine IL-17 A in combination with dual checkpoint blockade targeting CTLA-4 and PD-1 significantly enhances CD8+ T cell infiltration and effectively suppresses melanoma progression [22].